Qiagen（QGEN）株式概要
Qiagen N.V.は、生物学的サンプルを分子レベルの知見に変えるSample to Insightソリューションを世界中で提供しています。 詳細
QGEN Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Qiagen N.V. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$35.17 |
| 52週高値 | US$57.82 |
| 52週安値 | US$32.53 |
| ベータ | 0.64 |
| 1ヶ月の変化 | -12.01% |
| 3ヶ月変化 | -27.59% |
| 1年変化 | -20.54% |
| 3年間の変化 | -31.61% |
| 5年間の変化 | -36.17% |
| IPOからの変化 | 1,504.86% |
最新ニュース
Recent updates
新しいナラティブ • May 15
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Apr 30
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
ナラティブの更新 • Apr 29
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion
Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.ナラティブの更新 • Apr 10
QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns
Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.ナラティブの更新 • Mar 27
QGEN: Possible Sale Prospects Are Expected To Drive Future Returns
The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.ナラティブの更新 • Mar 12
QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns
The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.ナラティブの更新 • Feb 25
QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside
Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.ナラティブの更新 • Feb 11
QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks
Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.ナラティブの更新 • Jan 28
QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition
Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.Seeking Alpha • Jan 27
Qiagen: Takeover Optionality With A High-Quality Consumables Platform
Summary QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there’s renewed takeover speculation after reports that show they’re weighing strategic options. QGEN’s potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed. QGEN’s portfolio with Parse Biosciences adds single-cell sequencing scale, while 2026 automation launches would further deepen its differentiated workflow. I think QGEN now makes much more sense given the renewed M&A interest. But if deal talks fail or rumors cool, shares could de-rate, so my “Buy” rating is explicitly speculative. Read the full article on Seeking Alphaナラティブの更新 • Jan 08
QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions
Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).分析記事 • Jan 07
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued
Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...ナラティブの更新 • Dec 14
QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead
Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.ナラティブの更新 • Nov 29
QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms
Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.ナラティブの更新 • Nov 15
QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside
Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.分析記事 • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...ナラティブの更新 • Oct 31
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.ナラティブの更新 • Oct 17
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.ナラティブの更新 • Oct 03
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.ナラティブの更新 • Sep 04
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.分析記事 • Sep 02
Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality
Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...分析記事 • Aug 08
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...分析記事 • Aug 05
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk
NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...Seeking Alpha • Feb 25
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking Alpha株主還元
| QGEN | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 6.6% | 4.1% | 1.0% |
| 1Y | -20.5% | 8.3% | 28.7% |
業界別リターン: QGEN過去 1 年間で7.1 % の収益を上げたUS Life Sciences業界を下回りました。
リターン対市場: QGENは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。
価格変動
| QGEN volatility | |
|---|---|
| QGEN Average Weekly Movement | 5.0% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: QGEN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: QGENの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1984 | 5,500 | Thierry Bernard | www.qiagen.com |
Qiagen N.V.は、生物学的試料を分子レベルの知見に変換するsample to insightソリューションを世界中に提供しています。同社は、サンプル材料の核酸安定化精製キット、ジェノタイピング、遺伝子発現、ウイルスおよび細菌分析用の手動および自動処理、シリカ膜および磁気ビーズ技術などのサンプル技術消耗品、核酸精製用キットおよびコンポーネントなどの二次サンプル技術消耗品、核酸精製用機器、品質管理、アクセサリーを提供しています。また、結核検査用インターフェロン-γ遊離アッセイ、移植後検査用アッセイ、ウイルス量モニタリング用アッセイなどの免疫反応消耗品、出生前検査用アッセイ、性感染症およびHPV検出用アッセイ、ゲノムバリアント解析用アッセイなどの腫瘍学および性と生殖に関する健康消耗品、診断が困難な症候群のワンステップ分子解析、統合PCR検査などのサンプルからインサイトまでの機器も提供している。遺伝子発現、遺伝子型分類、遺伝子制御の解析のための定量PCR、逆転写、組み合わせキットなどの研究用PCR消耗品、QIAGENの装置やテクノロジーで実行されるヒトID/フォレンジックアッセイ消耗品、ヒトID用のショートタンデムリピートアッセイや食品汚染アッセイからなるヒトID/フォレンジックアッセイ消耗品、デジタルPCRやqPCRソリューションを含むPCR装置、開発・設定された酵素やPCRソリューションを提供。NGS遺伝子パネル、ライブラリー前処理キットおよびコンポーネント、全ゲノム増幅、DNAメチル化分析、QIAGEN消耗品および機器、バイオインフォマティクス・ソリューション、配列に基づくアッセイ法医学的遺伝子系譜サービスを提供。分子診断やライフサイエンス分野にサービスを提供している。同社は1984年に設立され、オランダのヴェンロに本社を置く。
Qiagen N.V. 基礎のまとめ
| QGEN 基礎統計学 | |
|---|---|
| 時価総額 | US$7.22b |
| 収益（TTM） | US$402.17m |
| 売上高(TTM) | US$2.10b |
18.1x
PER（株価収益率3.5x
P/SレシオQGEN は割高か？
公正価値と評価分析を参照収益と収入
| QGEN 損益計算書（TTM） | |
|---|---|
| 収益 | US$2.10b |
| 売上原価 | US$710.57m |
| 売上総利益 | US$1.39b |
| その他の費用 | US$986.13m |
| 収益 | US$402.17m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 1.94 |
| グロス・マージン | 66.15% |
| 純利益率 | 19.16% |
| 有利子負債／自己資本比率 | 50.0% |
QGEN の長期的なパフォーマンスは？
過去の実績と比較を見る| Qiagen 配当日 | |
|---|---|
| 配当落ち日 | Jul 07 2026 |
| 配当支払日 | Jul 14 2026 |
| 配当落ちまでの日数 | 45 days |
| 配当支払日までの日数 | 52 days |
QGEN 配当は確実ですか？
QGEN 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 05:34 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Qiagen N.V. 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。42
| アナリスト | 機関 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Charles Butler | Barclays |